Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ginkgo Biloba→

Ginkgo Biloba Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
90028-76-5
Molecular formula
Not available
Molecular weight
Not available
Drug class
Botanical extractflavonoid and terpene-lactone phytopharmaceutical
Mechanism of action
Standardised Ginkgo biloba leaf extracts contain flavonoid glycosides and terpene lactones, including ginkgolides and bilobalide. Proposed activities include antioxidant effects, modulation of platelet-activating factor, microcirculatory effects and neuroprotective signalling. Composition and pharmacology are extract-specific.
Indications / reported uses
  • Certain standardised Ginkgo biloba extracts are authorised or licensed in some countries for symptomatic treatment of mild cognitive impairment or age-related cognitive symptoms, and/or support of peripheral circulation. Uses cannot be generalised to all Ginkgo preparations or dietary supplements.

Sources: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=ginkgo.biloba2&lang=eng · https://pmc.ncbi.nlm.nih.gov/articles/PMC6488894/ · https://www.ncbi.nlm.nih.gov/books/NBK541024/

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ginkgo Biloba Environmental Risk Assessment (ERA) (the Ginkgo Biloba ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.